<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/912A09D1-F490-4385-96A8-6A7831A6E717"><gtr:id>912A09D1-F490-4385-96A8-6A7831A6E717</gtr:id><gtr:name>Gartnavel General Hospital, Glasgow</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/912A09D1-F490-4385-96A8-6A7831A6E717"><gtr:id>912A09D1-F490-4385-96A8-6A7831A6E717</gtr:id><gtr:name>Gartnavel General Hospital, Glasgow</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/37957E5A-1C60-42FF-B434-EFD81BFFBAAD"><gtr:id>37957E5A-1C60-42FF-B434-EFD81BFFBAAD</gtr:id><gtr:firstName>Ling-Pei</gtr:firstName><gtr:surname>Ho</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600371"><gtr:id>926A9BB6-A199-47A4-994A-6FFFCC6EC38A</gtr:id><gtr:title>Contribution of NKT cells to modulation of immunepathology in influenza infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600371</gtr:grantReference><gtr:abstractText>Recent emergence of deadly bird influenza (flu) strain affecting humans has highlighted how little we know of certain aspects of our body?s immune response during a flu infection. Lungs from individuals with fatal cases of bird flu were filled with a subset of white cells (T lymphocytes) which were meant to protect humans from viral infections. Therefore, was there an over-exuberant response by these T lymphocytes and did they cause more harm than good? 
We know that another group of immune cells (the natural killer T cells) can influence the behaviour of these T lymphocytes. We are using mouse models to determine if manipulating the natural killer T cells to put a brake on the expansion of the T lymphocytes might improve the outcome of bird flu infection in these mice. 
If this is the case, it could lead to new ways of treating severe flu infection and improve survival rate from new lethal strains of flu viruses like the H5N1 strain.</gtr:abstractText><gtr:technicalSummary>The actual cause of mortality and organ failure in influenza is unclear but a contributing cause is likely to be immunity-associated pathology and systemic response to the virus. In the recent outbreak of H5N1 avian influenza, all deaths were associated with diffuse alveolar damage, and filling of air space and interstitium with blood products and lymphocytes. It is clear that although cellular immunity is required to clear influenza virus and is known to afford protection, it could also be a source of tissue and organ injury. An optimal cellular immunity, therefore, requires a ?measured? response that would clear the virus with minimal bystander damage. This project aims to examine a potential mechanism by which T cell response may be controlled. It will determine the contribution of CD1d-restricted NKT cells to modulation of immune-pathology associated with influenza infection. We hypothesise that activation of NKT cells via local expression of CD1d in the lungs prevents the over-expansion of antigen-specific T cells and could limit immune-pathology during the immune response to influenza. We think that the cytolytic subset of NKT cells mediates this function and that enhancing the activity of NKT cells at the right point of an influenza virus infection could decrease the scale of immunepathology associated with cellular immunity. We have shown in preliminary studies that activation of NKT cells in mice with influenza A controls expansion of antigen-specific T cells and improved outcome of infection. This project will take these observations further by asking the following questions: i) is expansion of NKT cells contributed by local increase in expression of CD1d on the respiratory epithelium and resident antigen presenting cells (alveolar macrophages and lung dendritic cells) in the lungs? This will be relevant to the route of activation of NKT cells (eg intranasal rather than systemically). Does this local activation result in NKT cell activation and is there differential activation of the CD4+ cytokine producing and CD4-CD8+ cytolytic NKT subsets ii) how does activation of NKT cells affect immunepathology and mortality associated with influenza infection and iii) what is the route and timing of activation that will achieve optimal protective and anti-inflammatory effect in influenza infection. We will study these questions with three strains of Influenza A viruses of increasing pathogenicity and utilize both in vitro and in vivo models of influenza infection.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>299859</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:description>Genomic expression and changes in lungs of mice infected with influenza A virus.</gtr:description><gtr:id>D0D29B3E-85DD-4934-A8BB-CF12E0AEDF34</gtr:id><gtr:impact>Data in preparation for submission for publication</gtr:impact><gtr:outcomeId>T5nPybpzx9v-1</gtr:outcomeId><gtr:partnerContribution>Analysis of gene expression/transcriptomics. Data in preparation for publication</gtr:partnerContribution><gtr:piContribution>As above</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Anaesthetics</gtr:department><gtr:description>Immune changes in lungs during pandemic H1N1 infection</gtr:description><gtr:id>283566EE-2AD8-4B05-835A-B5445AF89B3A</gtr:id><gtr:impact>Data currently being analysed and paper (PlosOne 2010)</gtr:impact><gtr:outcomeId>DA9oBJEm6qg-1</gtr:outcomeId><gtr:partnerContribution>Patient cohort and data</gtr:partnerContribution><gtr:piContribution>We performed the immune cells analysis and broncho-alveolar lavage and blood sampling. Collaborator provided ITU support and help with bronchscopy and Ethics application</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>Investigating iNKT protection from immunepathology in H5N1 infleunza A virus infection in mice</gtr:description><gtr:id>E65B7A5B-7055-41E5-9756-77A725FE4A54</gtr:id><gtr:impact>Data which is currently being analysed.</gtr:impact><gtr:outcomeId>XUWygh5efxm-1</gtr:outcomeId><gtr:partnerContribution>NIMR provided the Category 4 facility required for inoculation of mice with H5N1 influenza A virus. He also provided the H5N1 influenza A virus</gtr:partnerContribution><gtr:piContribution>As above</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gartnavel General Hospital, Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Immune studies on patient with fatal or severe pdmH1N1</gtr:description><gtr:id>4A9180ED-DC68-472A-8EB0-BD35660EB9FC</gtr:id><gtr:impact>PLOSOne 2010</gtr:impact><gtr:outcomeId>i17S9cC3Qbv-1</gtr:outcomeId><gtr:partnerContribution>Paper (PLOSOne 2010)</gtr:partnerContribution><gtr:piContribution>Collaborator provided the patients' samples and virology support</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Science Week</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BDF1CC87-8074-48AF-A7F9-1544B8A128D6</gtr:id><gtr:impact>100 members of public attended - good response from floor during question time.

No</gtr:impact><gtr:outcomeId>H4vCjzN4Qfm</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Studentship - Regulation of innate immune response to influenza A virus infection (Suzanne Cole)</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>40198257-18A9-4F98-B4DD-1C64CDD80413</gtr:id><gtr:outcomeId>5462927cceede5.94419097</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Studentship - The role of NKT and regulatory T cells in immuneregulation in the lungs</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A598CA31-771D-499B-9D8C-0EF1B6E0D7FD</gtr:id><gtr:outcomeId>54628d3711ecf9.26929139</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEFCE - Developing a translational research programme for sarcoidosis</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>6BCFDA83-AF1F-4839-B82E-4A27563B14AD</gtr:id><gtr:outcomeId>DCxEYes2eWU0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - Identifying a gene expression signature for progressive pulmonary sarcoidosis</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:id>A3EECF57-CB13-41F4-A79C-A1705F526349</gtr:id><gtr:outcomeId>54628afd880d85.13526841</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Steering committee, NIHR Translational Research Partnership</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41B2C191-7306-4854-ADAD-C728BD5ED50E</gtr:id><gtr:impact>The Inflammatory Respiratory Disease Translational Research Partnership brings together world-class investigators in 26 of UK's leading academic and NHS research centres to support collaboration with the life sciences industry. The Partnership works with individual biopharmaceutical, device and diagnostic companies to drive research in the early and exploratory development of new respiratory drugs and other interventions.</gtr:impact><gtr:outcomeId>5462883e883ab1.06311013</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type><gtr:url>http://www.nocri.nihr.ac.uk/research-expertise/translational-research-partnerships/inflammatory-respiratory-disease/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Steering committee, British Thoracic Society</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AB0B2C6C-E8A3-4CF5-857B-0854E68EF7A0</gtr:id><gtr:outcomeId>546286c2a06f43.99888229</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Well characterized model of lung injury during high-pathogenicity flu virus infection</gtr:description><gtr:id>9C0C9FF0-4D45-47AC-8995-E6E9B434E8D9</gtr:id><gtr:impact>Paper (Vaccine 2010)</gtr:impact><gtr:outcomeId>iRwV5FtZ386</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HIgh pathogenicity influenza A virus lung injury model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9C66031A-9FC2-486F-BAC2-33AE91F81868</gtr:id><gtr:title>Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f933dbea8b20f8a0bd3b0c219dee817"><gtr:id>9f933dbea8b20f8a0bd3b0c219dee817</gtr:id><gtr:otherNames>Wegmann F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>pm_14908_28_22922673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3538EBA5-6C44-4AC4-8224-9CA6750C3645</gtr:id><gtr:title>M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02aa2ebb10d042b908ae932541a85e1"><gtr:id>f02aa2ebb10d042b908ae932541a85e1</gtr:id><gtr:otherNames>Cole SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>5a6f2eed5726b2.49427731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32F75328-34BB-4697-8ED8-2CDAE3A91465</gtr:id><gtr:title>MAIT cells are activated during human viral infections.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd9c5d3ad67e5b8adc8f4409ebdea785"><gtr:id>fd9c5d3ad67e5b8adc8f4409ebdea785</gtr:id><gtr:otherNames>van Wilgenburg B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>585d65e3cf4816.15666335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B36E111E-C9AD-48EC-9377-1F0665A9B49B</gtr:id><gtr:title>Abnormalities in iNKT cells are associated with impaired ability of monocytes to produce IL-10 and suppress T-cell proliferation in sarcoidosis.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52966806cd61b555488fbf562c7dc10b"><gtr:id>52966806cd61b555488fbf562c7dc10b</gtr:id><gtr:otherNames>Crawshaw A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5462856638ce13.19794795</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8E920ED-2360-48B7-8FCF-BC0D66483733</gtr:id><gtr:title>Natural killer T cells in asthma--toward increased understanding.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3744dbe1aa8c3b72c3e4f82972a51aaa"><gtr:id>3744dbe1aa8c3b72c3e4f82972a51aaa</gtr:id><gtr:otherNames>Ho LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>546230372fe5a3.07100265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E78AF63E-6AC9-4306-AB9A-F147732443FE</gtr:id><gtr:title>Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3744dbe1aa8c3b72c3e4f82972a51aaa"><gtr:id>3744dbe1aa8c3b72c3e4f82972a51aaa</gtr:id><gtr:otherNames>Ho LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>54628569910508.15683663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E961151-4EC7-4CAB-BDD0-1A658C99D2C2</gtr:id><gtr:title>Hepcidin regulation by innate immune and infectious stimuli.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13c9270163e5a00e5919e9e956c231ab"><gtr:id>13c9270163e5a00e5919e9e956c231ab</gtr:id><gtr:otherNames>Armitage AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_14908_28_21873546</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47B9A329-F171-4F2F-86FA-EBF8DD844D3E</gtr:id><gtr:title>Pivotal Advance: Invariant NKT cells reduce accumulation of inflammatory monocytes in the lungs and decrease immune-pathology during severe influenza A virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92802d214dd935bc6cacbd9b33a363ad"><gtr:id>92802d214dd935bc6cacbd9b33a363ad</gtr:id><gtr:otherNames>Kok WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>54628567938b58.06669782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD163F5F-7BC1-4ACD-8581-248D1EBD05DF</gtr:id><gtr:title>Involvement of the 4-1BB/4-1BBL pathway in control of monocyte numbers by invariant NKT cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02aa2ebb10d042b908ae932541a85e1"><gtr:id>f02aa2ebb10d042b908ae932541a85e1</gtr:id><gtr:otherNames>Cole SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>54628566621132.58758961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C27616B7-CA1C-4400-B9B0-6F9322E4717D</gtr:id><gtr:title>High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/673680106ade3187f249d2a683028495"><gtr:id>673680106ade3187f249d2a683028495</gtr:id><gtr:otherNames>Zhao Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5462856742d643.81416532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7384A72-2E30-4104-B208-5E6562D8FA2C</gtr:id><gtr:title>Alternative spliced CD1d transcripts in human bronchial epithelial cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b15937798803e7eaf8e0598acab90182"><gtr:id>b15937798803e7eaf8e0598acab90182</gtr:id><gtr:otherNames>Benam KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54628567b934c0.02802333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C040741C-2605-477A-956D-E621CC0DFD3B</gtr:id><gtr:title>IFITM3 restricts the morbidity and mortality associated with influenza.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8080feaaa6a1c8bc11a2811ee3812b4f"><gtr:id>8080feaaa6a1c8bc11a2811ee3812b4f</gtr:id><gtr:otherNames>Everitt AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>doi_14908_ature10921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F63D1269-1A42-4EF0-B988-CC691A636230</gtr:id><gtr:title>Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d0c6b9b627239f85e603ce8f8de6ade"><gtr:id>3d0c6b9b627239f85e603ce8f8de6ade</gtr:id><gtr:otherNames>Zhang YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>54628566de7f28.11518653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35AE5F64-299C-43C8-846E-C9FA780F588E</gtr:id><gtr:title>Activation of invariant NKT cells in early phase of experimental autoimmune encephalomyelitis results in differentiation of Ly6Chi inflammatory monocyte to M2 macrophages and improved outcome.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7cdc53e4d61940698b236b86f46c2a7"><gtr:id>b7cdc53e4d61940698b236b86f46c2a7</gtr:id><gtr:otherNames>Denney L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>546285676a68d2.84670719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74263E29-7730-4228-AB3A-D0D27289E4BD</gtr:id><gtr:title>Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/809479b55d0feae311ee786e90664f3d"><gtr:id>809479b55d0feae311ee786e90664f3d</gtr:id><gtr:otherNames>Krashias G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>546285696b8fa2.17581484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BE71F47-E520-4FC4-AA04-A0E15EE42E6A</gtr:id><gtr:title>A streamlined implementation of the glutamine synthetase-based protein expression system.</gtr:title><gtr:parentPublicationTitle>BMC biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8564bfa53ae6b4a72f7817544a1510f"><gtr:id>c8564bfa53ae6b4a72f7817544a1510f</gtr:id><gtr:otherNames>Knox R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1472-6750</gtr:issn><gtr:outcomeId>5462856687bc89.25566111</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E781CF0-D6B3-4B97-9152-EB63F766E486</gtr:id><gtr:title>Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db9a89e402a484ffe65964fd920c99fb"><gtr:id>db9a89e402a484ffe65964fd920c99fb</gtr:id><gtr:otherNames>Elderfield RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56ded7bd59aa28.25633743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>426A8F59-0B0C-48D7-AE2D-3D5C34648C50</gtr:id><gtr:title>Reduction of natural killer but not effector CD8 T lymphocytes in three consecutive cases of severe/lethal H1N1/09 influenza A virus infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7cdc53e4d61940698b236b86f46c2a7"><gtr:id>b7cdc53e4d61940698b236b86f46c2a7</gtr:id><gtr:otherNames>Denney L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54628568168625.70358562</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600371</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>